[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350188-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350188-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","acquired-resistance-of-cancer-therapies-mechanisms-and-perspectives","Acquired resistance of cancer therapies: Mechanisms and perspectives","","Over the past decades, cancer treatment has advanced through chemotherapy, targeted therapy, and immunotherapy, yet most patients still face treatment failure because tumors develop acquired resistance. This review explains how acquired resistance arises from tumor-intrinsic and tumor microenvironment–extrinsic factors, including selection of resistant clones, new genetic mutations, and microenvironmental remodeling. Recent concepts such as epigenetic alterations, lineage plasticity, metabolic reprogramming, and cellular crosstalk are integrated to guide translational strategies and next-generation combinations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/acquired-resistance-of-cancer-therapies-mechanisms-and-perspectives/350188/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/acquired-resistance-of-cancer-therapies-mechanisms-and-perspectives/350188.png","ImageObject",300,407,{"name":42,"@type":43},"Angel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is acquired resistance in cancer therapy?","Question",{"text":63,"@type":64},"Acquired resistance occurs when tumors initially respond to therapy but later develop resistance, leading to relapse and progression. It is a major limitation across chemotherapy, targeted therapy, and immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which mechanisms drive acquired resistance?",{"text":68,"@type":64},"Mechanisms are broadly divided into tumor-cell-intrinsic factors and extrinsic factors mediated by the tumor microenvironment (TME). Intrinsic examples include enhanced DNA repair and lineage plasticity, while extrinsic drivers involve TME components such as CAFs, TAMs, and hypoxia.",{"name":70,"@type":61,"acceptedAnswer":71},"What recent concepts are highlighted in the review?",{"text":72,"@type":64},"The review emphasizes advances including epigenetic alterations, lineage plasticity, metabolic reprogramming, and cellular crosstalk/signaling within the tumor microenvironment. These concepts support a framework for preventing or overcoming resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350188,1790167722,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review Article  \nAcquired resistance of cancer therapies: Mechanisms and perspectives  \nManli Wang1, Xiaoqian Zhai2,3, Jiayao Li4, Jiale Chen5, Xiyue Gai4, Xunxi Liu4, Yu Liu6, Qinghua Zhou3, Chong Chen4  \n1Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China;  \n2Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n3Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n4State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;  \n5West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China;  \n6Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.  \nAbstract  \nOver the past decades, significant progress has been made in cancer treatment, including chemotherapy, targeted therapy, and more recently, immunotherapy. However, only a limited number of patients achieve cure with these therapies. A major challenge lies in acquired resistance to cancer treatments, where patients initially respond but eventually develop resistance and relapse. The underlying mechanisms of acquired resistance are still emerging, encompassing both tumor cell-intrinsic and extrinsic factors, such as the selection of pre-existing resistant clones, acquired genetic mutations, and alterations in the tumor microenvironment. In recent years, several new concepts and significant advances have emerged in this field, such as epigenetic alterations, lineage plasticity, metabolic reprogramming, and cellular crosstalk and signaling within the tumor microenvironment. This review systematically summarizes these advances, aiming to provide a comprehensive theoretical framework that integrates emerging concepts of resistance, while also offering a translational perspective focused on identifying actionable therapeutic targets and guiding the development of next-generation combination strategies to prevent or overcome acquired resistance in the clinic.  \nKeywords: Cancer; Chemotherapy; Immunotherapy; Targeted therpay; Acquired resistance; Mechanisms; Lineage plasticity  \nIntroduction  \nCancer remains a leading cause of mortality worldwide. The therapeutic landscape has been profoundly reshaped by diverse modalities, including conventional chemotherapy, molecularly targeted therapy, and more recently, cancer immunotherapy. Chemotherapy, a cornerstone of systemic treatment for decades, employs cytotoxic agents to eliminate rapidly dividing tumor cells through mechanisms such as DNA damage, inhibition of microtubule dynamics, and interference with nucleic acid metabolism. [1] Targeted therapy has ushered in an era of precision oncology by specifically inhibiting oncogenic driver mutations in proteins like epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), kirsten rat sarcoma viral oncogene homolog (KRAS), and human epidermal growth factor receptor 2 (HER2), significantly improving patient outcomes in defined molecular subsets. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) and  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[www.cmj.org](www.cmj.org) |\n|  | DOI:\u003Cbr>10.1097/CM9.0000000000004048 |\n\ncytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has demonstrated unprecedented and durable responsesin a subset of patients across various malignancies by reactivating the host’s anti-tumor immune response. [2,3] Despite these remarkable advances, the long-term efficacy of all these cancer therapies is severely limited by the almost inevitable development of acquired resistance, wherein tumors that initially respond to treatment eventually relaps","cbCaieSEcHQ7KHey","https://ap.wps.com/l/cbCaieSEcHQ7KHey","pdf",13152079,31,"English","# Introduction\n## Cancer treatment modalities and the challenge of acquired resistance\n## Intrinsic and extrinsic mechanisms overview\n# Abstract","[{\"question\":\"What is acquired resistance in cancer therapy?\",\"answer\":\"Acquired resistance occurs when tumors initially respond to therapy but later develop resistance, leading to relapse and progression. It is a major limitation across chemotherapy, targeted therapy, and immunotherapy.\"},{\"question\":\"Which mechanisms drive acquired resistance?\",\"answer\":\"Mechanisms are broadly divided into tumor-cell-intrinsic factors and extrinsic factors mediated by the tumor microenvironment (TME). Intrinsic examples include enhanced DNA repair and lineage plasticity, while extrinsic drivers involve TME components such as CAFs, TAMs, and hypoxia.\"},{\"question\":\"What recent concepts are highlighted in the review?\",\"answer\":\"The review emphasizes advances including epigenetic alterations, lineage plasticity, metabolic reprogramming, and cellular crosstalk/signaling within the tumor microenvironment. These concepts support a framework for preventing or overcoming resistance.\"}]","Acquired resistance of cancer therapies: Mechanisms and perspectives | PDF",1790087596,78,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/714f772df7579d77e4598bec3902b7f4.webp",983,1324,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/189d087302adb0c6bc25470dcced82b4.webp",982,1323,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f6a50684edc5add288c82a9d9093205.webp",981,1321,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84310d10162a9fb81b3f87ba72bcf960.webp",980,1320]